What is the typical dose of vitamin K for correcting a coagulopathy?

Vitamin K Dosing for Coagulopathy Correction

For warfarin-associated coagulopathy in adults, administer 2.5 to 10 mg of vitamin K intravenously (up to 25 mg initially in severe cases), infused slowly over 15-30 minutes, combined with 4-factor prothrombin complex concentrate (4F-PCC) for major bleeding. 1, 2

Dosing Algorithm Based on Clinical Scenario

Major Bleeding (Life-Threatening)

• Vitamin K dose: 10 mg IV (slow infusion over 15-30 minutes in 25-50 mL normal saline) 1, 2
• Critical addition: Must be given with 4F-PCC for immediate reversal, as vitamin K alone takes 4-6 hours IV (18-24 hours oral) to work 1
• 4F-PCC dosing: Based on INR and weight
  • INR 2 to <4: 25 U/kg
  • INR 4-6: 35 U/kg
  • INR >6: 50 U/kg (max 5,000 units, capped at 100 kg) 1

Elevated INR Without Bleeding

• INR 5.0-10.0:

  • 1-2.5 mg oral vitamin K is sufficient and preferred 3, 4, 5
  • Achieves same 24-hour INR correction as IV with lower risk 5
  • Avoids overcorrection and warfarin resistance 6, 4

• INR >10.0:

  • 5 mg oral vitamin K 4
  • Alternative: 2.5-10 mg IV if oral route unavailable 2

Minor Bleeding

• 2.5-10 mg oral or IV vitamin K 2, 3
• Correct underlying bleeding source
• Monitor INR at 6-8 hours; repeat dose if inadequate response 2

Route-Specific Considerations

Intravenous administration (when unavoidable):

• Infuse slowly, not exceeding 1 mg per minute 2
• Dilute in 25-50 mL normal saline over 15-30 minutes 1
• More predictable and rapid (4-6 hours) than oral (18-24 hours) 1
• Modern preparations have eliminated historical anaphylaxis risk 1

Oral administration (preferred for non-emergent cases):

• Safer than IV or subcutaneous routes 4, 5
• Subcutaneous route is unpredictable and not recommended 1

Critical Pitfalls to Avoid

1. Don't give vitamin K alone for major bleeding: It provides no immediate correction. Always combine with 4F-PCC or fresh frozen plasma 1

2. Avoid high doses for mild over-anticoagulation: Doses >2.5 mg for INR 5-10 cause overcorrection (INR <2.0) in 17% of cases, creating thrombotic risk 6. Female patients are particularly susceptible to overcorrection 6

3. Don't use 3F-PCC when 4F-PCC is available: 4F-PCC is superior for INR normalization (OR: 3.50, p<0.0001) 7

4. Severe over-anticoagulation (INR >9.5 with APTT ratio >2): May require repeat dosing as single doses often fail to achieve INR ≤4.0 within 24 hours 8

5. Reassess at 6-8 hours: If INR not adequately corrected, repeat the vitamin K dose 2

Special Populations

Newborns with hemorrhagic disease:

• Treatment: 1 mg SC or IM 2
• Higher doses needed if mother received oral anticoagulants 2

Non-warfarin coagulopathy (antibiotics, malabsorption):

• 2.5-25 mg (rarely up to 50 mg) depending on severity 2

The evidence strongly supports a tiered approach: low-dose oral vitamin K (1-2.5 mg) for asymptomatic over-anticoagulation, and high-dose IV vitamin K (10 mg) with factor replacement for major bleeding. The 2020 ACC guideline 1 and FDA labeling 2 provide the most authoritative dosing framework, with research studies 3, 6, 4, 5 confirming that lower doses minimize overcorrection while effectively reducing INR.